NCT06175468View on ClinicalTrials.gov

"Evaluate the Efficacy and Safety of Formosa 1-Breath Free (NRICM101) in Subjects With the Symptoms of COVID-19 or Influenza-like Disease"

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

August 31, 2024

Conditions
Influenza Viral InfectionsCOVID-19
Interventions
DRUG

Formosa 1-Breath Free (NRICM101)

After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.

DRUG

Placebo control drug

After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.

Trial Locations (1)

Unknown

China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

Tian-I Pharmaceutical,. Co. Ltd.

UNKNOWN

collaborator

China Medical University, China

OTHER

collaborator

Qualitix Clinical Research Co., Ltd.

INDUSTRY

lead

China Medical University Hospital

OTHER

NCT06175468 - "Evaluate the Efficacy and Safety of Formosa 1-Breath Free (NRICM101) in Subjects With the Symptoms of COVID-19 or Influenza-like Disease" | Biotech Hunter | Biotech Hunter